# Clinical Evidence and Dosing of Semaglutide 2.4 mg for Weight Loss

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/semaglutide-2-4-mg-weight-loss-clinical-evidence-dosing/
> **Published:** 2026-06-19T23:54:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:04:11-04:00
> **Clinical Summary:** Explore semaglutide 2.4 mg weight loss clinical evidence and dosing protocols from the STEP 1 trial for effective obesity management in non-diabetic adults.

---

GLP-1 Clinical Relevance  #53Moderate Clinical Relevance  Relevant context for GLP-1 prescribers; interpret with care.
⚕ GLP-1 News  |  CED Clinic
Clinical TrialRandomized Controlled TrialObesity ManagementSemaglutideEndocrinologyAdults with ObesityWeight Loss OutcomesAppetite RegulationSTEP 1 TrialGlucagon-Like Peptide-1 AgonistDose OptimizationGastrointestinal Adverse Events

Why This Matters

The STEP 1 trial established semaglutide 2.4 mg as the effective maintenance dose for weight loss in non-diabetic patients, with demonstrated superiority over placebo and tirzepatide comparators, directly informing dosing protocols in primary care GLP-1 prescribing. Understanding the side effect profile and efficacy data from this landmark trial enables family physicians to appropriately counsel patients on realistic weight loss expectations, manage tolerability during titration, and make evidence-based decisions about patient selection and continuation therapy. This knowledge is essential for safe, effective implementation of GLP-1 therapy in the primary care setting where the majority of these medications are now prescribed.

Clinical Summary
The STEP 1 trial, a 68-week randomized controlled trial published in the New England Journal of Medicine in 2021, evaluated semaglutide 2.4 mg (the maximum approved dose, though some references cite 2.5 mg as the target maintenance dose) versus placebo in adults with obesity or overweight status but without diabetes. The trial demonstrated that semaglutide-treated patients achieved a mean weight loss of approximately 14% from baseline compared to 2.4% in the placebo group, representing a difference of approximately 10 percentage points in weight reduction. The drug was titrated over 16 weeks using a standard escalation protocol beginning at 0.25 mg weekly, with the primary endpoint being change in body weight from baseline to week 68.

Common adverse events in the semaglutide arm included gastrointestinal symptoms, primarily nausea, vomiting, and diarrhea. The incidence of nausea ranged from mild to moderate in most patients and was generally transient, diminishing over time as patients continued treatment. Discontinuation rates due to adverse events were higher in the semaglutide group compared to placebo, though the majority of patients who experienced gastrointestinal [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) remained on treatment. No serious pancreatitis or significant safety signals emerged during the trial period.

For prescribers, these findings establish semaglutide 2.4 mg as an effective pharmacologic intervention for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) in non-diabetic patients with obesity or overweight, with a substantial and clinically meaningful weight reduction that exceeds what is typically achieved with lifestyle modification alone. The predictable gastrointestinal tolerability profile allows for patient counseling and expectation management. The trial provides the evidence base supporting the use of this agent in primary care and specialty settings for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) in appropriate patient populations.

Clinical Takeaway

Clinical Takeaway

The STEP 1 trial demonstrated that semaglutide 2.4 mg weekly (the approved dose for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) in non-diabetic patients) produces significant weight loss averaging 14-15% of baseline body weight over 68 weeks, compared to approximately 2-3% with placebo. Gastrointestinal [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) including nausea, vomiting, and constipation occur frequently but typically decrease in frequency and severity over the first 4-8 weeks of therapy. For family medicine practitioners, titrating slowly from 0.25 mg and explicitly counseling patients about expected GI symptoms during weeks 1-4 improves [medication adherence](https://cedclinic.com/new-york-medical-cannabis-tax-repeal/) and reduces unnecessary discontinuation.

Dr. Caplan’s Take
“The STEP 1 trial remains one of the most clinically relevant datasets we have for understanding semaglutide’s efficacy in non-diabetic populations, and the 2.5 mg dose represents the sweet spot for many patients between meaningful weight loss and tolerability. What’s often overlooked in discussions of these trials is that the gastrointestinal [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/), particularly nausea, are dose and titration dependent, which means how we communicate the ramp-up schedule to patients directly impacts adherence and outcomes. I counsel my patients that starting low and titrating slowly over 16 weeks isn’t a limitation of the medication but rather the pathway to long-term success, since those who push dosing too quickly are far more likely to discontinue. The data shows us that at 2.5 mg, patients achieved approximately 12 percent weight loss over 68 weeks, but that number becomes clinically actionable only when

Clinical Perspective
🧠 The STEP 1 trial established semaglutide 2.4 mg as the effective maintenance dose for weight management in non-diabetic populations, though the article’s focus on 2.5 mg dosing reflects real-world prescribing variation that clinicians should recognize as off-label practice. Within the contemporary GLP-1 landscape, this dosing ambiguity underscores the importance of standardizing prescribing to evidence-based maintenance doses (2.4 mg for Wegovy, 1 mg for Ozempic in T2D) to ensure predictable efficacy and facilitate patient counseling on realistic treatment expectations. Clinicians should prioritize titration protocols aligned with FDA-approved dosing schedules while educating patients that supratherapeutic dosing does not confer additional metabolic benefit and increases adverse event risk, particularly gastrointestinal tolerability issues that drive therapy discontinuation.

💬 Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20%3Cb%3ESemaglutide%3C%2Fb%3E%202.5%20Mg%20Dosing%2C%20Benefits%2C%20And%20Side%20Effects.%20-%20Dr%20Sreelatha%20Red%20%40drcaplan&url=https%3A%2F%2Fwww.gidoc.net%2Fincludes%2Fpages%2F%3Fgid%3Dsemaglutide-2-5-mg)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.gidoc.net%2Fincludes%2Fpages%2F%3Fgid%3Dsemaglutide-2-5-mg)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20%3Cb%3ESemaglutide%3C%2Fb%3E%202.5%20Mg%20Dosing%2C%20Benefits%2C%20And%20Side%20Effects.%20-%20Dr%20Sreelatha%20Red%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fwww.gidoc.net%2Fincludes%2Fpages%2F%3Fgid%3Dsemaglutide-2-5-mg)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

📰 Source: [Google Alert – (Ozempic OR Wegovy OR Mounjaro OR Zepbound OR semaglutide OR tirzepatide OR liraglutide) AND (study OR trial OR research OR data OR doctors OR FDA)](https://www.gidoc.net/includes/pages/?gid=semaglutide-2-5-mg)

Nationwide GLP-1 Care
Looking for thoughtful, physician-led GLP-1 guidance?

 CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care.
 

[Learn More](https://cedclinic.com/metabolic/)
[Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services)

Table of Contents

- [FAQ](#FAQ)[What is semaglutide and how does it work?](#What_is_semaglutide_and_how_does_it_work)
- [Is semaglutide only for people with diabetes?](#Is_semaglutide_only_for_people_with_diabetes)
- [What was shown in the STEP 1 trial?](#What_was_shown_in_the_STEP_1_trial)
- [What is the typical starting dose of semaglutide?](#What_is_the_typical_starting_dose_of_semaglutide)
- [What are the common side effects of semaglutide?](#What_are_the_common_side_effects_of_semaglutide)
- [How much weight can I expect to lose with semaglutide?](#How_much_weight_can_I_expect_to_lose_with_semaglutide)
- [How long does it take to see results from semaglutide?](#How_long_does_it_take_to_see_results_from_semaglutide)
- [Is semaglutide a permanent solution for weight loss?](#Is_semaglutide_a_permanent_solution_for_weight_loss)
- [What happens if I stop taking semaglutide?](#What_happens_if_I_stop_taking_semaglutide)
- [Are there people who should not take semaglutide?](#Are_there_people_who_should_not_take_semaglutide)
- [Related](#Related)

## FAQ

#### What is semaglutide and how does it work?

Semaglutide is a GLP-1 receptor agonist medication that works by mimicking a natural hormone in your body that controls blood sugar and appetite. It helps you feel fuller longer and reduces hunger signals, which leads to eating less and losing weight.

#### Is semaglutide only for people with diabetes?

No, semaglutide can be prescribed to people without diabetes who have obesity or are overweight and need help with weight management. The STEP 1 clinical trial specifically studied adults without diabetes who used semaglutide successfully.

#### What was shown in the STEP 1 trial?

The STEP 1 trial was a major study published in the New England Journal of Medicine in 2021 that followed adults without diabetes for 68 weeks. It demonstrated that semaglutide was effective for weight loss in people with obesity and overweight conditions.

#### What is the typical starting dose of semaglutide?

Semaglutide treatment typically begins at lower doses and is gradually increased over time to help your body adjust and minimize side effects. Your doctor will determine the right dosing schedule based on your individual needs and tolerance.

#### What are the common side effects of semaglutide?

The most common side effects include nausea, vomiting, diarrhea, and constipation, especially when first starting the medication or increasing doses. These side effects are often temporary and tend to improve as your body adjusts to the medication.

#### How much weight can I expect to lose with semaglutide?

Weight loss results vary from person to person, but [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) have shown significant weight reduction in many patients. Your actual results will depend on your starting weight, lifestyle changes, diet, and exercise habits.

#### How long does it take to see results from semaglutide?

Most people begin to notice appetite reduction and early weight loss within the first few weeks of treatment. More significant weight loss typically occurs over several months of continued use combined with healthy eating and exercise.

#### Is semaglutide a permanent solution for weight loss?

Semaglutide is a tool to help with weight management, but it works best when combined with lifestyle changes like healthy eating and regular physical activity. Some people may need to continue the medication long-term to maintain their weight loss results.

#### What happens if I stop taking semaglutide?

If you stop taking semaglutide, your appetite typically returns to normal and you may regain some or all of the weight you lost. It is important to discuss any changes to your treatment plan with your doctor before stopping the medication.

#### Are there people who should not take semaglutide?

People with a personal or family history of certain thyroid cancers or multiple endocrine neoplasia should not take semaglutide. You should tell your doctor about all your medical conditions and medications so they can determine if semaglutide is safe for you.

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

RELATED READING AT CED CLINIC

Continue exploring the evidence

[GLP-1 Drugs: Clinical Evidence for Weight & Metabolic Health](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)

Review the latest clinical evidence on GLP-1 drugs and their impact on weight and [metabolic health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/).

[Learn More](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)

[Understanding the Semaglutide Side Effect Profile: Clinical Evidence](https://cedclinic.com/semaglutide-side-effect-profile-clinical-evidence/)

Explore detailed clinical data on the side effect profile of semaglutide to better manage patient expectations.

[Read Details](https://cedclinic.com/semaglutide-side-effect-profile-clinical-evidence/)

[Tirzepatide Weight Loss: Clinical Trial Evidence & Safety](https://cedclinic.com/tirzepatide-weight-loss-maintenance-evidence-safety/)

Compare clinical trial evidence and safety data of tirzepatide for weight loss and maintenance.

[Explore Now](https://cedclinic.com/tirzepatide-weight-loss-maintenance-evidence-safety/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).